Advances in Pharmacoepidemiology and Drug Safety

Evaluating Drug Safety and Effectiveness in Cancer Pharmacoepidemiology

Wang Sun^* Department of Epidemiology, University of California, Berkeley, United States of America
^*Correspondence: Wang Sun, Department of Epidemiology, University of California, Berkeley, United States of America, Email:

Received: 30-Aug-2024, Manuscript No. PDS-24-27217; Editor assigned: 02-Sep-2024, Pre QC No. PDS-24-27217 (PQ); Reviewed: 16-Sep-2024, QC No. PDS-24-27217; Revised: 23-Sep-2024, Manuscript No. PDS-24-27217 (R); Published: 30-Sep-2024, DOI: 10.35250/2167-1052.24.13.364

Description

Cancer pharmacoepidemiology is an essential area of research that combines the study of cancer treatment with the principles of epidemiology to understand how drugs impact cancer patients at a population level [1]. It is a growing discipline that seeks to provide valuable insights into the real-world effectiveness, safety and use of medications in cancer care [2]. The field not only focuses on the development of new drugs but also investigates the patterns of medication use, the side effects experienced by patients and how these medications influence long-term outcomes for cancer patients.

One of the core objectives of cancer pharmacoepidemiology is to evaluate the risks and benefits of medications in large, diverse patient populations. This is essential because clinical trials, while informative, are often conducted under highly controlled conditions that may not reflect how drugs perform in the real world. In clinical trials, patients are usually carefully selected based on specific criteria and the conditions of drug administration are tightly controlled [3]. However, once a drug is approved for public use, it may be prescribed to a broader group of patients, including those with different underlying health conditions or those who are taking other medications. Cancer pharmacoepidemiology aims to understand how these real-world factors influence the effectiveness and safety of cancer treatments [4].

The importance of cancer pharmacoepidemiology becomes even more evident when considering the complexity of cancer as a disease. Cancer is not a single condition but a group of diseases characterized by the uncontrolled growth of abnormal cells [5]. Each type of cancer may require a different treatment approach and patients may respond differently to the same medication. It is essential to study how cancer medications are used in practice and how they affect different groups of patients. By examining large datasets from hospitals, cancer registries and health insurance records, researchers can identify patterns in drug use and outcomes that can inform clinical decision-making and improve patient care.

One of the key areas of focus in cancer pharmacoepidemiology is the safety of cancer medications [6]. While these drugs are designed to target cancer cells, they can also affect healthy cells, leading to a range of side effects. Some of these side effects can be severe or even critical and understanding the risk factors for these adverse events is a critical component of pharmacoe- pidemiology. Researchers in this field work to identify which patients are most at risk for serious side effects and how to minimize these risks while still providing effective treatment. This information is invaluable for oncologists who must balance the benefits of a medication with the potential risks when making treatment decisions [7,8].

Another important aspect of cancer pharmacoepidemiology is studying the effectiveness of cancer drugs outside of the controlled environment of clinical trials [9,10].

Conclusion

In real-world settings, patients may not always take their medications as prescribed, or they may face other challenges that affect their ability to complete a course of treatment. For example, financial barriers, lack of access to healthcare, or other health conditions can all influence whether a patient follows their prescribed treatment plan. Pharmacoepidemiology helps to identify these barriers and understand how they impact the success of cancer treatments.

References

1. Hicks B, Kaye JA, Azoulay L, Kristensen KB, Habel LA, Pottegård A. The application of lag times in cancer pharmacoepidemiology: A narrative review. Ann Epidemiol. 2023;84:25-32.

   [Crossref] [Google Scholar] [PubMed]

2. Good  P , Haywood  A , Gogna  G , Martin  J , Yates P, Greer R, et al. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of Cannabidiol (CBD). BMC Palliat Care. 2019;18(1):110.

   [Crossref] [Google Scholar] [PubMed]

3. Tenhunen O, Turpeinen M, Kurki P. New study designs in clinical drug development. Duodecim. 2017;133(6):599-605.

   [Google Scholar]

4. Maltser S, Cristian A, Silver JK, Morris GS, Stout NL. A focused review of safety considerations in cancer rehabilitation. PM R. 2017;9(9S2):S415-S428.

   [Crossref] [Google Scholar] [PubMed]

5. Parekh N, Garg A, Choudhary R, Gupta M, Kaur G, Ramniwas S, et al. The role of natural flavonoids as telomerase inhibitors in suppressing cancer growth. Pharmaceuticals (Basel). 2023;16(4):605.

   [Crossref] [Google Scholar] [PubMed]

6. Fitzner K, Oteng-Mensah F, Donley P, Heckinger EAF. Safety of cancer therapies: At what cost? Popul Health Manag. 2017;20(4):318-328.

   [Crossref] [Google Scholar] [PubMed]

7. Tulsky JA, Steinhauser KE, LeBlanc TW, Bloom N, Lyna PR, Riley J, et al. Triadic agreement about advanced cancer treatment decisions: Perceptions among patients, families, and oncologists. Patient Educ Couns. 2022;105(4):982-986.

   [Crossref] [Google Scholar] [PubMed]

8. Loh KP, Abdallah M, Kadambi S, Wells M, Kumar AJ, Mendler JH, et al. Treatment decision-making in acute myeloid leukemia: A qualitative study of older adults and community oncologists. Leuk Lymphoma. 2021;62(2):387-398.

   [Crossref] [Google Scholar] [PubMed]

9. Rivera DR, McGlynn KA, Freedman AN. Connections between pharmacoepidemiology and cancer biology: designing biologically relevant studies of cancer outcomes. Ann Epidemiol. 2016;26(11):741-745.

   [Crossref] [Google Scholar] [PubMed]

10. Molfino A, Amabile MI, Giorgi A, Monti M, D'Andrea V, Muscaritoli M. Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials. Expert Opin Investig Drugs. 2019;28(8):733-740.

    [Crossref] [Google Scholar] [PubMed]